Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Wenyu Zhu; Qian Geng; Haoliang Peng; Zhihui Jin; Dongqing Li; Xiaolin Pu; Ge Wang; Hua Jiang

doi:10.3389/fonc.2022.802467

journal article Open Access Mar 17, 2022

Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Wenyu Zhu Qian Geng Haoliang Peng Zhihui Jin Dongqing Li

Xiaolin Pu Ge Wang

Hua Jiang

Frontiers in Oncology Vol. 12 · Frontiers Media SA

View at Publisher Save 10.3389/fonc.2022.802467

Abstract

The combination of immunotherapy and chemotherapy has a synergic effect in non-small cell lung cancer (NSCLC). However, the elderly are often excluded from clinical trails due to their poor health status and more comorbidities. We sought to assess the efficacy and safety of low-dose nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus tislelizumab (an anti-PD-1 antibody) in elderly patients with advanced NSCLC. In this phase 2 clinical trail, eligible patients were those aged ≥65 years with metastatic NSCLC who had disease progression after treatment with ≥1 line of chemotherapy or targeted therapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) variations were eligible if they demonstrated disease progression after treatment with ≥1 corresponding inhibitor. Primary endpoints were progression-free survival and safety/tolerability. Secondary endpoints included objective response rate and overall survival. Among 29 patients enrolled from May 2019 through August 2020, 21 (72.4%) had adenocarcinoma, 17 (58.6%) had a performance status of 2, 8 (27.6%) had asymptomatic brain metastases, and 13 (44.8%) had EGFR/ALK variations. As of the data cutoff point on April 1, 2021, median progression-free survival and overall survival were 9.5 months and 16.5 months, respectively. Ten patients achieved a partial response (objective response rate of 34.5%). Seventeen (58.6%) patients had ≥1 treatment-related adverse event, with grade 3 events seen in 3 patients (10.3%). The most common adverse events were fatigue (20.7%), fever (17.2%), abnormal liver function (17.2%), and rash (17.2%). These results suggest that low-dose nab-paclitaxel plus tislelizumab is well tolerated and effective in elderly patients with advanced NSCLC, including those with EGFR/ALK variations.

Topics

No keywords indexed for this article. Browse by subject →

References

35

[1]

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al.

CA: A Cancer Journal for Clinicians 2018 10.3322/caac.21492

[2]

Lung cancer: current therapies and new targeted treatments

Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine et al.

The Lancet 2017 10.1016/s0140-6736(16)30958-8

[3]

Yi "Immune Signature-Based Risk Stratification and Prediction of Immune Checkpoint Inhibitor's Efficacy for Lung Adenocarcinoma" Cancer Immunol Immunother (2021) 10.1007/s00262-020-02817-z

[4]

Zhang "Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects" Front Pharmacol (2018) 10.3389/fphar.2018.01253

[5]

Heymach "Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology" J Clin Oncol (2018) 10.1200/jco.2017.77.0446

[6]

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel et al.

New England Journal of Medicine 2018 10.1056/nejmoa1801005

[7]

Kon "Immune Checkpoint Inhibitor Combinations: Current Efforts and Important Aspects for Success" Drug Resist Update (2019) 10.1016/j.drup.2019.07.004

[8]

Morel "Combining Epigenetic Drugs With Other Therapies for Solid Tumours - Past Lessons and Future Promise" Nat Rev Clin Oncol (2020) 10.1038/s41571-019-0267-4

[9]

Bonanno "Treatment Strategies for Locally Advanced non-Small Cell Lung Cancer in Elderly Patients: Translating Scientific Evidence Into Clinical Practice" Crit Rev Oncol Hematol (2021) 10.1016/j.critrevonc.2021.103378

[10]

Townsley "Analysis of Treatment Practices for Elderly Cancer Patients in Ontario, Canada" J Clin Oncol (2005) 10.1200/jco.2005.06.742

[11]

Desai "Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared With Cremophor-Based Paclitaxel" Clin Cancer Res (2006) 10.1158/1078-0432.ccr-05-1634

[12]

Socinski "Safety and Efficacy of Weekly Nab(R)-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Elderly Patients With Advanced Non-Small-Cell Lung Cancer" Ann Oncol (2013) 10.1093/annonc/mds461

[13]

Anzai "Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel Monotherapy as Second-Line Therapy of Cytotoxic Anticancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer" Med (Baltimore) (2017) 10.1097/md.0000000000009320

[14]

Sakata "Phase II Trial of Weekly Nab-Paclitaxel for Previously Treated Advanced non-Small Cell Lung Cancer: Kumamoto Thoracic Oncology Study Group (KTOSG) Trial 1301" Lung Cancer (2016) 10.1016/j.lungcan.2016.06.009

[15]

Liu "A Phase II Open-Label Clinical Study of Comparing Nab-Paclitaxel With Pemetrexed as Second-Line Chemotherapy for Patients With Stage IIIB/IV non-Small-Cell Lung Cancer" Med Oncol (2015) 10.1007/s12032-015-0660-5

[16]

Dahan "FcgammaRs Modulate the Anti-Tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis" Cancer Cell (2015) 10.1016/j.ccell.2015.09.011

[17]

Zhang "The Binding of an Anti-PD-1 Antibody to FcgammaRIota has a Profound Impact on its Biological Functions" Cancer Immunol Immunother (2018) 10.1007/s00262-018-2160-x

[18]

Liu "Tislelizumab: An Investigational Anti-PD-1 Antibody for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)" Expert Opin Investig Drugs (2020) 10.1080/13543784.2020.1833857

[19]

Apetoh "Combining Immunotherapy and Anticancer Agents: The Right Path to Achieve Cancer Cure" Ann Oncol (2015) 10.1093/annonc/mdv209

[20]

Galluzzi "Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents" Cancer Cell (2015) 10.1016/j.ccell.2015.10.012

[21]

Zitvogel "Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance" Immunity (2013) 10.1016/j.immuni.2013.06.014

[22]

Peng "Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-kappaB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer" Cancer Res (2015) 10.1158/0008-5472.can-14-3098

[23]

Zhang "Upregulation of Programmed Cell Death Ligand 1 Promotes Resistance Response in non-Small-Cell Lung Cancer Patients Treated With Neo-Adjuvant Chemotherapy" Cancer Sci (2016) 10.1111/cas.13072

[24]

Arrieta "Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial" JAMA Oncol (2020) 10.1001/jamaoncol.2020.0409

[25]

Oncology Meets Immunology: The Cancer-Immunity Cycle

Daniel S. Chen, Ira Mellman

Immunity 2013 10.1016/j.immuni.2013.07.012

[26]

Wang "Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial" JAMA Oncol (2021) 10.1001/jamaoncol.2021.0366

[27]

Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis

Chee Khoon Lee, Johnathan Man, Sally Lord et al.

Journal of Thoracic Oncology 2017 10.1016/j.jtho.2016.10.007

[28]

Oya "Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer With ALK Rearrangement" Int J Mol Sci (2020) 10.3390/ijms21072623

[29]

Shi "A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients With Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)" J Thorac Oncol (2014) 10.1097/jto.0000000000000033

[30]

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck, Tony S K Mok, Makoto Nishio et al.

The Lancet Respiratory Medicine 2019 10.1016/s2213-2600(19)30084-0

[31]

Chason "Metastatic Carcinoma in the Central Nervous System and Dorsal Root Ganglia. A Prospective Autopsy Study" Cancer (1963) 10.1002/1097-0142(196306)16:6<781::aid-cncr2820160614>3.0.co;2-m

[32]

Nussbaum "Brain Metastases. Histology, Multiplicity, Surgery, and Survival" Cancer (1996) 10.1002/(sici)1097-0142(19961015)78:8<1781::aid-cncr19>3.0.co;2-u

[33]

Zimm "Intracerebral Metastases in Solid-Tumor Patients: Natural History and Results of Treatment" Cancer (1981) 10.1002/1097-0142(19810715)48:2<384::aid-cncr2820480227>3.0.co;2-8

[34]

Veccia "Management of Brain Metastases From Lung Cancer in the Era of Immunotherapy: A Review of the Literature" Future Oncol (2021) 10.2217/fon-2020-0701

[35]

Bunn "Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer" J Natl Cancer Inst (2003) 10.1093/jnci/95.5.341

Metrics

13

Citations

35

References

Details

Published: Mar 17, 2022
Vol/Issue: 12
License: View

Authors

Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, Gansu, China; School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 100049, China

Contribution from the Institut Européen de Chimie et Biologie, 2 rue Robert Escarpit, 33607 Pessac Cedex, France, Laboratoire de Pharmacochimie, 146 rue Léo Saignat, 33076 Bordeaux, France, and Institut de Chimie de la Matière Condensée de Bordeaux, 87 Avenue du Docteur Schweitzer, 33608 Pessac Cedex, France

Funding

Chinese Society of Clinical Oncology

Cite This Article

Wenyu Zhu, Qian Geng, Haoliang Peng, et al. (2022). Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.802467

Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

You May Also Like